Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results